BB-301 Shows Durable Efficacy: Benitec Biopharma Reports Strengthening Clinical Responses Over 24 Months
Market Chameleon (Mon, 12-Jan 7:10 AM)
BNTC Achieves 100% Response Rate in Early BB-301 Trial—FDA Fast Track Signals Potential Shift in OPMD Treatment
Market Chameleon (Mon, 3-Nov 7:36 AM)
